EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, EZZ Life Science Holdings's Enterprise Value is A$36.32 Mil.
EZZ Life Science Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$4.15 Mil. Therefore, EZZ Life Science Holdings's EV-to-FCF for today is 8.74.
The historical rank and industry rank for EZZ Life Science Holdings's EV-to-FCF or its related term are showing as below:
ASX:EZZ'
s EV-to-FCF Range Over the Past 10 Years
Min: 1.04 Med: 3.74 Max: 45.14
Current: 8.42
During the past 4 years, the highest EV-to-FCF of EZZ Life Science Holdings was 45.14. The lowest was 1.04. And the median was 3.74.
ASX:EZZ's EV-to-FCF is ranked worse than 50.26% of 382
companies
in the Biotechnology industry
Industry Median: 8.405
vs ASX:EZZ: 8.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of EZZ Life Science Holdings's EV-to-FCF
For the Biotechnology subindustry, EZZ Life Science Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's EV-to-FCF falls into.
EZZ Life Science Holdings's current Enterprise Value is A$36.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$4.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EZZ Life Science Holdings's PE Ratio for today is calculated as:
EZZ Life Science Holdings's share price for today is A$1.095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.082.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
EZZ Life Science Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of EZZ Life Science Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
EZZ Life Science Holdings (ASX:EZZ) Business Description
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:EZZ has been successfully added to your